Sudarshan Pharma Industries is expanding its API manufacturing capacity with an investment of Rs 25.50 crore. In this regard, the company has executed a definitive agreement with Srigen Lifesciences for the transfer of capital assets - comprising land, building, and plant & machinery - at fully operational manufacturing facility located in Telangana. The acquired facility will be utilized for the production of high-value, technically complex pharmaceutical ingredients including Ropivacaine, Bupivacaine, Probenecid (Probalan), Sitagliptin, Apixaban, and Rivaroxaban - critical APls and intermediates with strong demand across regulated and semi-regulated markets.

Through this investment, the company aims to increase its manufacturing capacity and accelerate its trajectory in the high-growth Active Pharmaceutical Ingredients (APl) and specialty chemicals sectors, resulting into incremental footprint in the domestic and global market.

Sudarshan Pharma Industries is engaged in contract manufacturing, outsource & Supply of Generic Pharma formulation and medicines to healthcare institution, Government, NGO and Hospitals.